International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 32, Issue 5, May 2026 **ijppr.humanjournals.com** ISSN: 2349-7203

Artificial Intelligence in Diabetes Pharmacotherapy: Drug Discovery, Personalized Medicine, and Clinical Applications

Mr. Manvendra Singh[1], Prof (Dr.) Santosh Kumar Mishra[2], Miss. Rupalee Verma, Miss. Shivani Tiwari[2]

Department of Pharmacology, Sagar college of Pharmacy, India.

Received: 27 March 2026 Revised: 22 April 2026 Accepted: 28 April 2026

ABSTRACT

Diabetes Mellitus continues to pose a significant global health burden due to its increasing prevalence and associated complications. Conventional pharmacotherapy often follows a generalized approach, which may not adequately address inter-individual variability in disease progression and treatment response. In recent years, Artificial Intelligence has emerged as a transformative tool in healthcare, offering innovative solutions for improving diabetes management. This review explores the expanding role of AI in diabetes pharmacotherapy, with particular emphasis on drug discovery, personalized medicine, and clinical decision-making. AI-driven algorithms enable rapid identification of novel therapeutic targets, virtual screening of bioactive compounds, and drug repurposing, thereby accelerating the drug development process. Furthermore, AI facilitates precision medicine by integrating patient-specific data, including genetic, metabolic, and lifestyle factors, to optimize therapeutic regimens and predict glycemic trends. In clinical settings, AI-based decision support systems and wearable technologies contribute to real-time monitoring and improved glycemic control. Despite these advancements, challenges such as data privacy concerns, lack of standardized regulatory frameworks, and high implementation costs remain significant barriers to widespread adoption. Overall, the integration of AI into diabetes pharmacotherapy represents a paradigm shift toward more efficient, predictive, and patient-centered care, with promising implications for future therapeutic strategies.

Keywords: Artificial Intelligence; Diabetes Mellitus; Pharmacotherapy; Machine Learning; Personalized Medicine; Drug Discovery; Glycemic Control; Clinical Decision Support System

1. INTRODUCTION

1.1 Overview of Diabetes Mellitus

Diabetes Mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia resulting from defects in insulin secretion, insulin action, or both. Over time, uncontrolled blood glucose levels lead to damage of various organs, particularly the eyes, kidneys, nerves, heart, and blood vessels.

1.1.1 Types of Diabetes Mellitus

a) Type 1 Diabetes Mellitus (T1DM)

- Caused by autoimmune destruction of pancreatic β-cells
- Leads to absolute insulin deficiency
- Common in children and young adults
- Requires lifelong insulin therapy



Fig 1: Type 1 Diabetes Mellitus

b) Type 2 Diabetes Mellitus (T2DM)

- Most common form (~90–95% cases)
- Characterized by insulin resistance + relative insulin deficiency
- Strongly associated with obesity, sedentary lifestyle, and genetics
- Managed with oral hypoglycemics, insulin, and lifestyle modification



Fig 2: Type 2 Diabetes Mellitus

c) Gestational Diabetes Mellitus (GDM)

- Develops during pregnancy

- Due to hormonal changes causing insulin resistance
- Usually resolves after delivery but increases future risk of T2DM



Fig 3: Gestational Diabetes Mellitus

1.1.2 Limitations of conventional pharmacotherapy

Conventional pharmacotherapy for Diabetes Mellitus is primarily based on standardized treatment protocols that often fail to account for individual variability in genetics, disease progression, and response to therapy. This generalized approach frequently leads to suboptimal glycemic control, as patients may respond differently to commonly used drugs such as Metformin, sulfonylureas, or insulin. Additionally, many antidiabetic agents are associated with adverse effects, including hypoglycemia, weight gain, gastrointestinal disturbances, and long-term organ-related complications, which can reduce patient adherence. Another major limitation is the progressive nature of diabetes, where monotherapy often becomes insufficient over time, necessitating combination therapy that increases treatment complexity and cost. Furthermore, conventional drug development is time-consuming, expensive, and has a high failure rate, delaying the availability of more effective therapies. Current pharmacotherapy also lacks real-time adaptability, as treatment adjustments are typically based on periodic clinical assessments rather than continuous monitoring of patient data. Importantly, these approaches do not adequately address underlying pathophysiological mechanisms such as inflammation, oxidative stress, and β-cell dysfunction at an individualized level. Consequently, there is a growing need for more precise, dynamic, and patient-centered therapeutic strategies, which has paved the way for the integration of advanced technologies like Artificial Intelligence in diabetes management.

1.1.3 Need for precision medicine

The growing burden and heterogeneity of Diabetes Mellitus highlight the urgent need for a more individualized therapeutic approach, as conventional treatment strategies often fail to achieve optimal glycemic control across diverse patient populations. Diabetes is not a uniform disease; rather, it encompasses multiple pathophysiological pathways involving variations in insulin resistance, β-cell dysfunction, genetic predisposition, lifestyle factors, and comorbid conditions. As a result, patients exhibit significant differences in drug response, efficacy, and susceptibility to adverse effects. For instance, while Metformin remains a first-line therapy, its effectiveness and tolerability vary considerably among individuals due to genetic and metabolic differences. Precision medicine aims to address these challenges by integrating patient-specific data—such as genomic profiles, biochemical markers, clinical history, and real-time glucose monitoring—to tailor therapeutic interventions more accurately. This approach enables optimized drug selection, dose individualization, and early prediction of treatment outcomes, thereby improving efficacy and minimizing adverse effects. Moreover, precision medicine supports proactive disease management by identifying high-risk individuals and enabling early intervention. The incorporation of advanced computational tools, particularly Artificial Intelligence, further enhances this paradigm by analyzing complex datasets to generate predictive and personalized treatment strategies.

Consequently, precision medicine represents a critical shift toward more effective, patient-centered care in diabetes pharmacotherapy.

1.1.4 Entry of Artificial Intelligence in pharmacology

The integration of Artificial Intelligence (AI) into pharmacology represents a significant shift from traditional, experience-based approaches toward data-driven and predictive decision-making. With the rapid expansion of biomedical data—including genomic information, clinical records, and real-time patient monitoring—conventional analytical methods have become insufficient to process and interpret such complex datasets. AI, particularly machine learning and deep learning techniques, has emerged as a powerful tool capable of identifying hidden patterns, predicting drug responses, and optimizing therapeutic strategies with greater accuracy and efficiency.



Fig 4: Artificial Intelligence in pharmacology

In pharmacology, AI initially gained prominence in drug discovery and development, where it is used to identify novel drug targets, perform virtual screening of compounds, and predict pharmacokinetic and pharmacodynamic properties. This has significantly reduced the time and cost associated with traditional drug development processes. Over time, the application of AI has expanded into clinical pharmacology, enabling personalized treatment planning, dose optimization, and adverse drug reaction prediction based on individual patient characteristics.

Furthermore, AI has facilitated the development of advanced clinical decision support systems (CDSS), which assist healthcare professionals in selecting appropriate medications and adjusting therapies in real time. In the context of diabetes management, AI-driven tools can analyze continuous glucose monitoring data, lifestyle inputs, and treatment history to recommend individualized therapeutic interventions. This transition marks the evolution of pharmacology into a more precise, adaptive, and patient-centered discipline, where AI serves as a critical enabler of next-generation pharmacotherapy.

1.2 Fundamentals of AI in Pharmacology

a) Machine Learning (ML)

Machine Learning (ML) is a branch of Artificial Intelligence that enables computer systems to learn patterns from data and make predictions or decisions without being explicitly programmed. In healthcare and pharmacology, ML plays a crucial role in analyzing large datasets such as patient records, laboratory values, and drug response profiles. ML algorithms are broadly categorized into supervised, unsupervised, and reinforcement learning.



Fig 5: Machine Learning

In supervised learning, models are trained using labeled datasets to predict outcomes like blood glucose levels or drug efficacy. Unsupervised learning identifies hidden patterns or clusters in data, which can help classify patient subgroups in diseases like Diabetes Mellitus. Reinforcement learning focuses on decision-making through trial and error, often used in optimizing treatment strategies. ML significantly enhances drug discovery by predicting molecular interactions and identifying potential drug candidates. It also supports clinical decision-making by forecasting disease progression and personalizing therapy. Despite its advantages, ML depends heavily on data quality and requires careful validation to ensure reliability. Overall, ML serves as a foundational tool for modern pharmacology, enabling more efficient, predictive, and personalized healthcare solutions.

b) Deep Learning (DL)

Deep Learning (DL) is an advanced subset of Machine Learning that uses multi-layered neural networks to model complex patterns in large datasets. Unlike traditional ML, which may require manual feature extraction, DL automatically identifies relevant features through hierarchical layers of processing. This makes it particularly effective in handling high-dimensional data such as medical images, genomic sequences, and continuous monitoring data. In pharmacology, DL is widely applied in drug discovery, disease diagnosis, and prediction of therapeutic outcomes.

For example, DL models can analyze retinal images to detect diabetic retinopathy or process continuous glucose monitoring data to predict glycemic trends in patients with Diabetes Mellitus. Additionally, DL facilitates virtual drug screening by predicting how chemical compounds interact with biological targets. The architecture of DL typically includes input layers, multiple hidden layers, and an output layer, enabling the system to learn increasingly abstract representations of data. Although DL offers high accuracy and automation, it requires large datasets, high computational power, and may lack interpretability. Nevertheless, DL is transforming pharmacology by enabling deeper insights and more precise therapeutic interventions.

c) Neural Networks

Neural Networks are computational models inspired by the structure and function of the human brain. They consist of interconnected units called neurons, organized into layers: input, hidden, and output layers. Each neuron processes information and passes it to the next layer through weighted connections, allowing the network to learn patterns from data. Neural networks form the backbone of both Machine Learning and Deep Learning systems. In pharmacology and healthcare, they are used to model complex biological relationships, predict drug responses, and analyze patient data.



Fig 6: Neural Networks

For instance, neural networks can predict insulin requirements, classify disease severity, or identify risk factors associated with Diabetes Mellitus. They are also used in pharmacokinetic and pharmacodynamic modeling to understand how drugs behave in the body. Neural networks learn through a process called training, where the model adjusts weights based on errors in prediction, improving accuracy over time. While highly powerful, neural networks can be computationally intensive and sometimes act as "black boxes," making interpretation challenging. Despite these limitations, they remain essential tools in modern pharmacology, enabling advanced predictive analytics and decision-making.

d) Big Data in healthcare

Big Data in healthcare refers to the massive volume of structured and unstructured data generated from various sources such as electronic health records (EHRs), laboratory reports, wearable devices, imaging systems, and genomic databases. The concept of Big Data is often described using the "5 Vs": volume, velocity, variety, veracity, and value. In pharmacology, Big Data provides a rich resource for understanding disease patterns, drug responses, and patient outcomes. It plays a critical role in enabling Artificial Intelligence systems, as large datasets are required to train accurate predictive models. In the context of Diabetes Mellitus, Big Data allows continuous monitoring of blood glucose levels, lifestyle patterns, and treatment responses, facilitating personalized care. It also supports population-level studies, helping identify risk factors and optimize treatment guidelines. However, managing Big Data poses challenges related to data privacy, integration, storage, and standardization. Advanced analytical tools and cloud computing technologies are often required to process such vast datasets efficiently. Overall, Big Data serves as the backbone of AI-driven healthcare, enabling more informed, data-driven decisions and improving the quality of pharmacological interventions.

1.3 AI in Drug Discovery for Diabetes

Artificial Intelligence (AI) has significantly transformed the early stages of drug discovery in Diabetes Mellitus by enhancing target identification, virtual screening, and drug repurposing processes. In target identification, AI algorithms analyze large-scale biological datasets, including genomics, proteomics, and metabolomics, to identify key molecular targets such as insulin receptors and glucagon-like peptide-1 (GLP-1) signaling pathways that play crucial roles in glucose homeostasis. These systems can uncover complex interactions and previously unrecognized therapeutic targets with high precision. Once targets are identified, AI facilitates virtual screening of compounds by rapidly evaluating thousands to millions of chemical structures to predict their binding affinity, pharmacokinetic properties, and potential efficacy, significantly reducing the need for time-consuming and costly laboratory experiments. Machine learning models can simulate molecular docking and predict drug–target interactions, thereby accelerating lead compound selection. Additionally, AI-driven drug repurposing has emerged as a powerful strategy, where existing drugs are analyzed for new therapeutic uses based on shared molecular pathways or biological effects. This approach reduces development time and enhances safety profiles since repurposed drugs already have established clinical data. For instance, AI-based platforms have been employed to design and screen novel analogues of Metformin by optimizing its structure to improve efficacy and minimize side effects. Similarly, AI techniques have enabled the identification of novel inhibitors targeting dipeptidyl peptidase-4 (DPP-4), an important enzyme involved in incretin degradation, thereby enhancing insulin secretion and glycemic control. By integrating computational modeling with biological data, AI not only improves the efficiency and accuracy of drug discovery but also enables the development of more targeted and effective antidiabetic therapies.

Table 1: AI in Drug Discovery for Diabetes

Aspect	Explanation (Short)
Target Identification	AI analyzes biological data (genomics, proteomics) to identify key targets like insulin receptors and GLP-1 pathways involved in glucose regulation.
Virtual Screening of Compounds	AI rapidly screens thousands of chemical compounds to predict binding affinity, efficacy, and safety, reducing time and cost of drug discovery.
Drug Repurposing	AI identifies new therapeutic uses for existing drugs by analyzing molecular pathways and biological similarities.
AI-based Screening for Metformin Analogues	AI optimizes metformin structure to develop improved analogues with better efficacy and fewer side effects.
Identification of Novel DPP-4 Inhibitors	AI predicts and designs new compounds that inhibit DPP-4 enzyme, enhancing incretin activity and insulin secretion.

1.4 AI in Personalized Medicine

The integration of Artificial Intelligence into personalized medicine has significantly advanced the management of Diabetes Mellitus by enabling patient-specific, data-driven therapeutic strategies. Unlike conventional approaches that follow generalized treatment protocols, AI facilitates individualized treatment planning by analyzing diverse datasets, including genetic profiles, clinical history, lifestyle factors, dietary patterns, and real-time physiological parameters. This allows clinicians to design tailored pharmacotherapeutic regimens that improve treatment efficacy and minimize adverse effects. One of the most impactful applications of AI in diabetes care is the development of glucose prediction models. These models utilize machine learning algorithms to analyze continuous streams of glucose data and predict future glycemic trends, thereby allowing early intervention to prevent hyperglycemia or hypoglycemia. Such predictive capabilities are particularly valuable in optimizing insulin therapy and maintaining stable glycemic control. Furthermore, AI plays a crucial role in dose optimization by dynamically adjusting drug dosages based on individual patient responses, metabolic variability, and changing physiological conditions. This reduces the risk of complications associated with over- or under-dosing, especially in insulin-dependent patients. The integration of AI with continuous glucose monitoring (CGM) systems has further enhanced diabetes management by enabling real-time data collection and analysis. Wearable devices equipped with CGM sensors continuously track glucose levels and, when combined with AI algorithms, provide automated recommendations for insulin dosing, dietary modifications, and lifestyle adjustments. This creates a closed-loop system, often referred to as an artificial pancreas, which significantly improves patient outcomes and quality of life. In addition to real-time monitoring, AI-driven risk prediction models are increasingly being used to identify individuals at high risk of developing diabetes-related complications, such as neuropathy, nephropathy, and cardiovascular diseases. These models analyze longitudinal patient data to detect subtle patterns and early warning signs, enabling proactive and preventive healthcare interventions. Moreover, AI supports clinical decision-making by integrating all these aspects into comprehensive decision support systems that assist healthcare providers in selecting the most appropriate therapeutic strategies for each patient. Despite these advantages, challenges such as data privacy, algorithm transparency, and the need for high-quality datasets remain important considerations. Nevertheless, the application of AI in personalized medicine represents a paradigm shift toward precision pharmacotherapy, offering more accurate, adaptive, and patient-centered management of diabetes.

Table 2: AI in Clinical Decision-Making

Component	Explanation
Smart Insulin Dosing Systems	AI-based systems analyze real-time glucose data, dietary intake, and patient activity to recommend precise insulin doses. These systems reduce the risk of hypoglycemia and improve glycemic control by continuously adapting to patient-specific needs.
AI-Powered Diagnostic Tools	AI algorithms assist in early detection and diagnosis of complications associated with Diabetes Mellitus by analyzing medical images, lab reports, and clinical data with high accuracy.
Clinical Decision Support Systems (CDSS)	AI-driven CDSS provide evidence-based recommendations to healthcare professionals by integrating patient history, drug interactions, and clinical guidelines, improving treatment decisions and reducing errors.
Integration with Wearable Devices	AI is integrated with wearable technologies such as continuous glucose monitors and smartwatches to track real-time physiological data, enabling automated alerts, treatment adjustments, and remote patient monitoring.

1.5 AI in Diabetes Monitoring and Management

The integration of Artificial Intelligence into the monitoring and management of Diabetes Mellitus has revolutionized patient care by enabling continuous, real-time, and personalized disease tracking. One of the most significant advancements is real-time glucose prediction, where AI algorithms analyze continuous glucose monitoring (CGM) data along with variables such as diet, physical activity, medication, and circadian patterns to forecast future blood glucose levels. These predictive models allow early detection of impending hyperglycemia or hypoglycemia, enabling timely interventions and reducing the risk of acute complications. Furthermore, the incorporation of AI into mobile health applications has expanded access to diabetes management tools, allowing patients to monitor their condition through smartphones. These AI-powered mobile apps provide features such as glucose tracking, dietary recommendations, medication reminders, and personalized insights based on individual health data, thereby improving patient engagement and adherence to therapy. In addition, remote patient monitoring has emerged as a key application of AI, particularly in the context of telemedicine. Healthcare providers can remotely access patient data, analyze trends using AI-driven analytics, and make informed clinical decisions without requiring frequent hospital visits. This approach is especially beneficial for chronic disease management, as it enhances continuity of care and reduces healthcare burden. Advanced CGM systems such as Dexcom G6 and FreeStyle Libre exemplify the integration of AI in real-world clinical practice. These devices continuously measure interstitial glucose levels and transmit data to mobile devices, where AI algorithms interpret the data to provide actionable insights, trend analysis, and predictive alerts. They also support integration with insulin delivery systems, contributing to the development of automated or semi-automated “artificial pancreas” systems. Moreover, AI enhances long-term disease management by identifying patterns in glucose variability, assessing treatment effectiveness, and recommending lifestyle modifications tailored to individual patients. Despite these advancements, challenges such as data privacy, device accuracy, and accessibility remain areas of concern. Nevertheless, AI-driven monitoring systems represent a paradigm shift from episodic to continuous care, enabling proactive, data-driven, and patient-centric management of diabetes, ultimately improving clinical outcomes and quality of life.

1.6 Advantages of AI in Diabetes Pharmacotherapy

a) Early Diagnosis

Artificial Intelligence enables early detection of Diabetes Mellitus by analyzing large volumes of patient data, including laboratory results, medical history, and lifestyle factors. AI algorithms can identify subtle patterns and risk markers long before clinical symptoms become evident. This allows timely intervention, prevention of disease progression, and reduction in long-term complications.

b) Precision Therapy

AI facilitates personalized treatment by integrating patient-specific information such as genetic profile, metabolic status, comorbidities, and drug response. This helps clinicians select the most appropriate drug, dose, and treatment strategy for each individual, improving therapeutic outcomes while minimizing adverse effects. It supports the concept of tailored pharmacotherapy rather than a “one-size-fits-all” approach.

c) Reduced Trial-and-Error Prescribing

Traditional pharmacotherapy often involves multiple adjustments before achieving optimal glycemic control. AI reduces this trial-and-error process by predicting patient responses to specific drugs based on historical and real-time data. This leads to faster achievement of treatment goals, improved patient compliance, and reduced risk of complications such as hypoglycemia.

d) Cost-Effectiveness

Although initial implementation of AI systems may be expensive, it ultimately reduces overall healthcare costs by minimizing unnecessary investigations, hospital visits, and ineffective treatments. Early diagnosis, optimized therapy, and better disease control lead to fewer complications, thereby lowering long-term medical expenses for both patients and healthcare systems.

Table 3: Challenges and Limitations

Challenge	Explanation
Data Privacy Issues	The use of Artificial Intelligence relies heavily on large volumes of sensitive patient data, including medical records and real-time monitoring information. This raises concerns regarding data security, confidentiality, and potential misuse, especially in managing Diabetes Mellitus.
Lack of Standardization	There is no universal framework for developing and implementing AI models in healthcare. Variability in data formats, algorithms, and validation methods can lead to inconsistent results and reduced reliability across different clinical settings.
High Cost of AI Systems	The development, implementation, and maintenance of AI technologies require significant financial investment, including advanced infrastructure, software, and skilled personnel, making accessibility limited in resource-constrained settings.
Regulatory Concerns	AI-based tools in pharmacotherapy face challenges in regulatory approval due to evolving guidelines, lack of clear policies, and concerns about safety, accountability, and ethical use in clinical decision-making.

Future Perspectives

The future of Artificial Intelligence in the management of Diabetes Mellitus is highly promising, with several emerging innovations expected to redefine pharmacotherapy and patient care. One of the most exciting directions is the integration of AI with nanotechnology, where intelligent algorithms can be used to design and optimize nanocarriers for targeted drug delivery. AI can predict particle size, drug loading efficiency, release kinetics, and biological interactions of nanoformulations, thereby accelerating the development of advanced systems such as nanoemulsions, liposomes, and polymeric nanoparticles. This integration enhances drug bioavailability, reduces side effects, and ensures site-specific delivery, making treatment more efficient and safer.

Another important advancement is AI-driven herbal drug discovery, which aligns well with current research trends in phytopharmacology. AI tools can analyze vast phytochemical databases to identify bioactive compounds from medicinal plants with potential antidiabetic activity. By predicting molecular targets, pharmacokinetic properties, and toxicity profiles, AI significantly reduces the time required for screening and validation of herbal candidates. This approach not only supports evidence-based herbal medicine but also bridges the gap between traditional knowledge and modern pharmacology, offering new opportunities for developing safer and cost-effective therapies.

Furthermore, the development of fully automated insulin delivery systems represents a major breakthrough in diabetes management. These systems, often referred to as “artificial pancreas,” integrate continuous glucose monitoring with AI algorithms and insulin pumps to create a closed-loop system. The AI continuously analyzes glucose levels and automatically adjusts insulin delivery in real time, minimizing human intervention. This leads to improved glycemic control, reduced risk of hypoglycemia, and enhanced quality of life for patients.

Overall, these advancements highlight a shift toward more intelligent, adaptive, and patient-centered therapeutic strategies. As technological capabilities continue to evolve, the convergence of AI with nanotechnology, herbal drug research, and automated delivery systems is expected to play a pivotal role in shaping the future of diabetes pharmacotherapy.

Conclusion

In conclusion, the integration of Artificial Intelligence into the pharmacotherapy of Diabetes Mellitus represents a transformative advancement in modern healthcare. This review highlights how AI-driven approaches have significantly improved multiple aspects of diabetes management, including drug discovery, personalized medicine, clinical decision-making, and continuous disease monitoring. By leveraging large-scale biomedical data and advanced computational models, AI enables early diagnosis, precise therapeutic interventions, and real-time adaptation of treatment strategies, thereby overcoming many limitations associated with conventional pharmacotherapy.

Furthermore, AI has accelerated the identification of novel drug targets, optimized treatment regimens, and facilitated the development of intelligent monitoring systems such as continuous glucose sensors and automated insulin delivery devices. The incorporation of AI into personalized medicine has shifted the treatment paradigm from a generalized approach to a patient-centric model, enhancing therapeutic efficacy while minimizing adverse effects. Despite these promising advancements, challenges such as data privacy concerns, lack of standardization, high implementation costs, and evolving regulatory frameworks must be addressed to ensure safe and equitable adoption of AI technologies in clinical practice.

Looking ahead, the convergence of AI with emerging fields such as nanotechnology and phytopharmacology holds immense potential for developing innovative and more effective therapeutic strategies. As research continues to evolve, AI is expected to play a central role in achieving precision pharmacotherapy and improving long-term clinical outcomes. Overall, the application of AI in diabetes pharmacotherapy marks a paradigm shift toward smarter, more efficient, and patient-focused healthcare systems, paving the way for the future of medicine.

REFERENCES

1. Contreras I, Vehi J. Artificial intelligence for diabetes management. *J Med Internet Res.* 2018;20(5):e10775.
2. Guan Z, et al. Artificial intelligence in diabetes management. *Front Endocrinol.* 2023;14:12424542.
3. Khalifa M, et al. Artificial intelligence for diabetes: enhancing prevention and management. *Smart Health.* 2024.
4. Daza A, et al. Clinical applications of artificial intelligence in diabetes. *Smart Health.* 2024.
5. Garg S, et al. AI in predicting drug responses in type 2 diabetes. *Diabetes Ther.* 2025.
6. Khokhar PB, et al. Advances in AI for diabetes prediction. *Artif Intell Med.* 2025.
7. Parab R, et al. Artificial intelligence in diabetes care: applications and implications. *Endocr Pract.* 2025.
8. Parab R, et al. AI advancements in diabetes care. *Cureus.* 2025.
9. Ghosh K, et al. Artificial intelligence in personalized medicine for diabetes. *Cureus.* 2025.
10. Fujihara K, et al. Machine learning approach to diabetes treatment strategies. *Diabetes Metab J.* 2023.
11. Tasin I, et al. Diabetes prediction using machine learning. *Healthc Technol Lett.* 2022.
12. Osonuga A, et al. AI in predictive analysis of diabetes therapy. *Ann Transl Med.* 2025.
13. Vettoretti M, et al. Advanced diabetes management using AI and CGM. *Sensors.* 2020.
14. Aiello M, et al. Machine learning and AI in diabetes prediction. *Comput Methods Programs Biomed.* 2019.
15. Shapiro MR, et al. AI-based drug repurposing in diabetes. *Diabetologia.* 2025.
16. Osonuga A, et al. AI-driven precision medicine in diabetes. *Ann Transl Med.* 2025.
17. Parab R, et al. AI-enabled biomarker identification in diabetes. *Endocr Pract.* 2025.
18. Khokhar PB, et al. ML techniques in diabetes prediction. *Artif Intell Med.* 2025.
19. Contreras I, Vehi J. Decision support systems in diabetes. *J Med Internet Res.* 2018.
20. Vettoretti M, et al. Artificial pancreas and AI integration. *Sensors.* 2020.
21. Garg S, et al. Predictive modeling of drug response in diabetes. *Diabetes Ther.* 2025.
22. Khalifa M, et al. AI in healthcare systems. *Smart Health.* 2024.
23. Daza A, et al. Deep learning in diabetes diagnosis. *Smart Health.* 2024.
24. Guan Z, et al. AI-based risk prediction models in diabetes. *Front Endocrinol.* 2023.
25. Ghosh K, et al. AI-driven personalized treatment in diabetes. *Cureus.* 2025.
26. Fujihara K, et al. Machine learning for insulin therapy optimization. *Diabetes Metab J.* 2023.
27. Tasin I, et al. ML-based diabetes prediction system. *Healthc Technol Lett.* 2022.
28. Osonuga A, et al. AI models for glycemic control. *Ann Transl Med.* 2025.
29. Vettoretti M, et al. Glucose prediction using AI. *Sensors.* 2020.
30. Parab R, et al. AI in clinical decision support systems. *Endocr Pract.* 2025.
31. Khalifa M, et al. AI applications in chronic disease management. *Smart Health.* 2024.
32. Khokhar PB, et al. ML evaluation metrics in diabetes prediction. *Artif Intell Med.* 2025.
33. Garg S, et al. Data-driven diabetes pharmacotherapy. *Diabetes Ther.* 2025.
34. Shapiro MR, et al. AI in immunotherapy for diabetes. *Diabetologia.* 2025.
35. Osonuga A, et al. AI in treatment optimization. *Ann Transl Med.* 2025.
36. Guan Z, et al. AI-based lifestyle risk prediction in diabetes. *Front Endocrinol.* 2023.
37. Contreras I, Vehi J. AI challenges in diabetes management. *J Med Internet Res.* 2018.

How to cite this article:
Mr. Manvendra Singh et al. Ijppr.Human, 2026; Vol. 32 (5): 202-211.

Conflict of Interest Statement: All authors have nothing else to disclose.